IL-31 Antikörper (AA 21-120)
Kurzübersicht für IL-31 Antikörper (AA 21-120) (ABIN1715124)
Target
Alle IL-31 (IL31) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 21-120
-
Verwendungszweck
- IL-31 Polyclonal Antibody
-
Kreuzreaktivität
- Maus
-
Homologie
- Rat
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from mouse IL-31
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB(1:300-5000),
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- IL-31 (IL31) (Interleukin 31 (IL31))
-
Andere Bezeichnung
- IL-31
-
Hintergrund
-
Synonyms: Interleukin-31, 1700013B14RIK, IL31, interleukin-31 precursor.
Background: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia and skin lesions, and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
-
Gen-ID
- 76399
Target
-